HER-2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine

Research output: Contribution to journalArticle

Abstract

The oncoprotein encoded by the HER-2 oncogene is a member of the HER family of receptor tyrosinekinases and is actually the first successfully exploited target molecule in new biomolecular therapies of solid tumors. The association of HER-2 overexpression with human tumors, its extracellular accessibility, as well as its involvement in tumor aggressiveness are all factors that make this receptor an appropriate target for tumor-specific therapy. In addition, HER-2 overexpression fosters its immunogenicity, as shown by the frequency of B and T cell-mediated responses against this oncoprotein in cancer patients, and it is being investigated as a promising molecule for either passive and active immunotherapy strategies. This review summarizes a number of immune intervention approaches that target HER-2 in breast cancer.

Original languageEnglish
Pages (from-to)10-18
Number of pages9
JournalJournal of Cellular Physiology
Volume205
Issue number1
DOIs
Publication statusPublished - Oct 2005

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cell Biology
  • Physiology

Fingerprint Dive into the research topics of 'HER-2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine'. Together they form a unique fingerprint.

  • Cite this